New drug safety trial offers hope for cGVHD patients in india
NCT ID NCT07135973
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants take the drug for up to 24 weeks, and doctors monitor for side effects and how well the disease responds. The goal is to see if belumosudil is safe enough for broader use in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belumosudil (a tablet taken by mouth)
What this could lead to
If it works, this could confirm that belumosudil is a safe option for managing chronic graft-versus-host disease in Indian patients.
What could go wrong
This is a small, single-arm safety study with only 26 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••